奥赛康(002755) - 2021 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2021 was ¥931,463,073.42, representing a 31.33% increase compared to ¥709,235,498.92 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥178,253,558.11, a significant increase of 67.35% from ¥106,515,696.82 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥172,943,472.48, up 69.97% from ¥101,748,199.76 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.19, reflecting a 72.73% increase from ¥0.11 in the same period last year[8]. - Operating revenue rose by 31.33% to ¥931,463,073.42 from ¥709,235,498.92, primarily due to improved sales as the pandemic situation improved[17]. - Net profit increased by 66.45% to ¥176,718,029.26 from ¥106,166,637.56, driven by revenue growth and cost reduction initiatives[17]. - The total comprehensive income for the period was ¥176,307,221.73, compared to ¥106,324,628.60 in the previous period, indicating an increase of about 66%[59]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,838,196,582.88, a slight increase of 0.79% from ¥3,808,099,396.51 at the end of the previous year[8]. - The net assets attributable to shareholders increased by 5.88% to ¥3,205,065,006.59 from ¥3,027,151,332.35 at the end of the previous year[8]. - Total assets increased to ¥7,668,522,392.40 from ¥7,665,386,657.59, reflecting a growth of 0.02%[50]. - Total liabilities decreased to ¥114,175,362.77 from ¥107,075,799.99, indicating a reduction of approximately 6.2%[50]. - The total equity attributable to shareholders increased to ¥7,554,347,029.63 from ¥7,558,310,857.60, a slight decline of 0.05%[50]. Cash Flow - The net cash flow from operating activities decreased by 68.93% to ¥53,577,910.12 from ¥172,458,289.64 in the same period last year[8]. - Cash inflow from operating activities was 1,030,349,230.33, a decrease from 1,040,373,771.94 in the prior period[72]. - Cash inflow from investment activities totaled 211,537,164.42, compared to 100,010,488.00 in the previous period[72]. - Net cash flow from investment activities was -602,526,901.86, worsening from -52,459,968.67 year-over-year[72]. - Cash and cash equivalents decreased by 39.96% to ¥822,063,450.30 from ¥1,369,098,462.16 due to new structured deposits purchased during the period[17]. - Cash and cash equivalents at the end of the period were 816,928,482.81, down from 1,304,226,310.39 in the previous period[74]. Expenses - Total operating costs amounted to ¥740,518,907.54, an increase from ¥592,159,611.81 in the previous period, reflecting a growth of approximately 25%[53]. - Research and development expenses surged by 67.19% to ¥79,979,264.90 from ¥47,836,244.95, reflecting increased investment in innovative and biological drug development[17]. - Sales expenses increased to ¥559,589,834.09 from ¥430,650,515.20, which is an increase of approximately 30%[53]. - The company reported a tax expense of ¥23,102,003.01, up from ¥19,192,208.15, reflecting an increase of about 20%[56]. Shareholder Information - The top shareholder, Nanjing Aosaikang Investment Management Co., Ltd., holds 34.20% of the shares, totaling 317,470,588 shares[11]. - The total number of ordinary shareholders at the end of the reporting period was 23,024[11]. Other Financial Metrics - The company's retained earnings rose to ¥181,497,075.62 from ¥185,460,903.59, a decrease of 2.1%[50]. - Deferred income tax liabilities remained stable at approximately ¥15,489,103.81 compared to ¥15,492,194.73[40]. - The company received government subsidies amounting to ¥4,640,947.26 during the reporting period[8]. - Other income for the period was reported at ¥3,850,321.01, up from ¥1,805,980.08, representing an increase of approximately 113%[53]. - Investment cash flow net amount was -¥602,526,901.86, a 1048.55% increase in outflow compared to -¥52,459,968.67, mainly due to increased purchases of structured deposits[17].